



**HAL**  
open science

**Psychiatric and psychological follow-up of undergraduate and postgraduate medical students: prevalence and associated factors. Results from the national BOURBON study. Running title: mental health and addictive behavior of medical students**

Guillaume Fond, A. Bourbon, C. Lançon, Mohamed Boucekine,  
Micoulaud-Franchi Jean-Arthur, Pascal Auquier, L. Boyer

► **To cite this version:**

Guillaume Fond, A. Bourbon, C. Lançon, Mohamed Boucekine, Micoulaud-Franchi Jean-Arthur, et al.. Psychiatric and psychological follow-up of undergraduate and postgraduate medical students: prevalence and associated factors. Results from the national BOURBON study. Running title: mental health and addictive behavior of medical students. *Psychiatry Research*, 2019, 272, pp.425-430. 10.1016/j.psychres.2018.12.174 . hal-02473615

**HAL Id: hal-02473615**

**<https://amu.hal.science/hal-02473615>**

Submitted on 10 Feb 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

**Inflammatory DEpression Advances in Schizophrenia (IDEAS): a precision medicine approach of the national FACE-SZ cohort.**

Running title: inflammatory depression in schizophrenia

**Fond G<sup>a,c</sup>, MD PhD, Godin O<sup>a,p</sup>, PhD, Schürhoff F<sup>a,b</sup>, MD PhD, Berna F<sup>a,e</sup>, MD PhD, Aouizerate B<sup>a,d,n</sup>, MD PhD, Capdevielle D<sup>a,f</sup>, MD PhD, Chereau I<sup>a,g</sup>, MD, D'Amato T<sup>a,h</sup>, MD PhD, Dubertret C<sup>a,i</sup>, MD PhD, Dubreucq J<sup>a,j</sup>, MD, Faget C<sup>a,c</sup>, MD PhD, Leignier S<sup>a,j</sup>, MD, Lançon C<sup>a,c</sup>, MD PhD, Mallet J<sup>a,i</sup>, MD PhD, Marulaz L<sup>a,b</sup>, MD, Misdrahi D<sup>a,d,o</sup>, MD, Passerieux C<sup>a,l</sup>, MD PhD, Rey R<sup>a,h</sup>, MD, Schandrin A<sup>a,f</sup>, MD, Urbach M<sup>a,l</sup>, MD, Vidailhet P<sup>e</sup>, MD PhD, Leboyer M<sup>a,b</sup>, MD PhD, Boyer L<sup>a,c</sup>, Llorca PM<sup>a,g</sup>, MD PhD**

**And the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group\***

<sup>a</sup> Fondation FondaMental, Créteil, France

<sup>b</sup> INSERM U955, équipe de psychiatrie translationnelle, Créteil, France, Université Paris-Est Créteil, DHU Pe-PSY, Pôle de Psychiatrie des Hôpitaux Universitaires H Mondor, Créteil, France

<sup>c</sup> Aix-Marseille Univ, Faculté de Médecine - Secteur Timone, EA 3279: CEReSS - Centre d'Etude et de Recherche sur les Services de Santé et la Qualité de vie, 27 Boulevard Jean Moulin, 13005 Marseille, France

<sup>d</sup> Centre Hospitalier Charles Perrens, F-33076 Bordeaux, France; Université de Bordeaux

<sup>e</sup> Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM U1114, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France

<sup>f</sup> Service Universitaire de Psychiatrie Adulte, Hôpital la Colombière, CHRU Montpellier, Université Montpellier 1, Inserm 1061, Montpellier, France.

<sup>g</sup> CMP B, CHU, EA 7280 Faculté de Médecine, Université d'Auvergne, BP 69 63003 Clermont-Ferrand Cedex 1, France.

<sup>h</sup> INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon, Université Claude Bernard Lyon 1, Equipe PSYR2, Centre Hospitalier Le Vinatier, Pole Est, 95 bd Pinel, BP 30039, 69678 Bron Cedex, France.

<sup>i</sup> AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, Inserm U894, Université Paris Diderot, Sorbonne Paris Cité, Faculté de médecine, France.

<sup>j</sup> Centre Référent de Réhabilitation Psychosociale, CH Alpes Isère, Grenoble, France.

<sup>l</sup> Centre Hospitalier de Versailles, Service de psychiatrie et d'addictologie adulte, Le Chesnay, EA 4047 HANDIReSP, UFR des Sciences de la Santé Simone Veil, Université Versailles Saint-Quentin-en-Yvelines, Versailles, France

<sup>n</sup> INRA, NutriNeuro, University of Bordeaux, U1286 F-33076 Bordeaux, France

<sup>o</sup> CNRS UMR 5287-INCIA

<sup>p</sup> Sorbonne Universités, UPMC Univ Paris 06, UMR\_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F-75013, Paris, France, INSERM, UMR\_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F-75013, Paris, France

**\* Correspondence should be sent to: Dr Guillaume FOND**

Aix-Marseille Univ, Faculté de Médecine - Secteur Timone, EA 3279: CEReSS - Centre d'Etude et de Recherche sur les Services de Santé et la Qualité de vie, 27 Boulevard Jean Moulin, 13005 Marseille, France

Tel: (33 6 68 10 22 58), e-mail: guillaume.fond@ap-hm.fr

Word count: 1837

## **Abstract**

**Background.** Major Depressive Disorder (MDD) is a therapeutic challenge in schizophrenia (SZ). Untangling different forms of MDD appears as the best current strategy to improve **remission** to treatment in the so-called precision medicine approach.

**Aims.** The objectives of the present study were to determine (i) the prevalence of Inflammatory Depression (ID) in stabilized SZ outpatients (ii) if ID was associated with clinical or cognitive profiles that may help clinicians detecting ID (iii) if antidepressants were effective in ID and (iv) the biological correlates of ID that may orientate personalized treatments.

**Method.** Participants were consecutively included and received a thorough 2 days-clinical assessment.

**Results.** 785 subjects were recruited in the FACE-SZ cohort. 289 (36.8%) were diagnosed with MDD (remitted or unremitted), of them 57 with ID (19.7%). No clinical or cognitive features were associated with ID (all  $p > 0.05$ ). ID has been associated with increased abdominal perimeter (aOR=4.48,  $p = 0.002$ ) and latent Toxoplasma infection (aOR=2.19,  $p = 0.04$ ). While antidepressants were associated with decreased depressive symptoms level in ID, 44% of the subjects remained unremitted under antidepressant, with no association with CRP blood levels.

**Conclusions.** **ID may not differ from other forms of depression by its clinical symptoms but by its aetiologies. ID is associated with increased perivisceral fat and latent Toxoplasma infection that** are both potentially related to gut/microbiota disturbances. Specific anti-inflammatory drugs and microbiota-targeted therapeutics appear as promising strategies in the treatment of inflammatory depression in schizophrenia.

**Declaration of interest.** None.

Keywords: depression, inflammation, schizophrenia, adiposity, Toxoplasma

## **Introduction**

Detecting and treating major depressive disorder remains a therapeutic challenge in schizophrenia (SZ). Recent studies have shown that stabilized SZ outpatients have high rates of major depression, with poor antidepressant administration and high treatment-resistance rates (Guillaume Fond et al., 2018). The last decade has shown that chronic low-grade peripheral inflammation plays a major role in depression onset and maintenance (Valkanova et al., 2013). In schizophrenia, peripheral inflammation has been specifically associated with depressive symptoms (Faugere et al., 2018) and antidepressant consumption (Fond et al., 2016). However, it remains unclear if inflammatory depression (ID) differs from non-inflammatory depression (NID) in SZ subjects, from a clinical and biological point of view. Inflammation has been also associated with SZ cognitive impairment (Bulzacka et al., 2016) in increased suicide risk in general population and depressive disorders ((Batty et al., 2018; Cáceda et al., 2018) for review see (Brundin et al., 2015)). The following sources of inflammation have been identified in both general population and psychiatric samples: addictions (tobacco smoking, alcohol and cannabis consumption), history of childhood trauma, overweight, sleep disorders and lack of physical activity (for review see (Berk et al., 2013)). Psychotropic drugs may influence inflammatory status. In non-SZ subjects, Selective Serotonin Reuptake inhibitors (SSRI) have shown anti-inflammatory properties (Hannestad et al., 2011) while tricyclic have been associated with higher inflammation in SZ subjects (Fond et al., 2017). Antipsychotic drugs may also have differential effects on peripheral inflammation (Fond et al., 2017).

The objectives of the present study were to determine (i) the prevalence of Inflammatory Depression (ID) in stabilized SZ outpatients (ii) if ID was associated with clinical or cognitive profiles that may help clinicians detecting ID (iii) if antidepressants were effective in ID and (iv) the biological correlates of ID that may orientate personalized treatments.

## **Population and methods**

### *Study design*

The FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) cohort is based on a French national network of 10 Schizophrenia Expert Centers (Bordeaux, Clermont-Ferrand, Colombes, Créteil, Grenoble, Lyon, Marseille, Montpellier, Strasbourg, Versailles), set up by a scientific cooperation foundation in France, the FondaMental Foundation ([www.fondation-fondamental.org](http://www.fondation-fondamental.org)) and pioneered by the French Ministry of Research in order to create a platform that links thorough and systematic assessment to research (Schürhoff et al., 2015).

#### *Study population*

Consecutive clinically stable patients (defined by no hospitalization and no treatment changes during the 8 weeks before evaluation) with a DSM-IV-TR diagnosis of schizophrenia or schizoaffective disorder were consecutively included in the study. Diagnosis was confirmed by two trained psychiatrists of the Schizophrenia Expert Centres network. All subjects were referred by their general practitioner or psychiatrist who subsequently received a detailed evaluation report with suggestions for personalized interventions.

#### *Data collected*

Patients were interviewed by members of the specialized multidisciplinary team of the Expert Center. Diagnoses interviews were carried out by two independent psychiatrists according to the Structured Clinical Interview for Mental Disorders (SCID 1.0).

#### *ID definition*

Depressive symptoms were evaluated using the Calgary Depression Rating Scale for Schizophrenia (CDRS (Addington et al., 1992; Lançon et al., 2000)). A score  $\geq 6$  is considered as a current major depressive episode. The CDRS is the most widely used scale for assessing depression in SZ. It has excellent psychometric properties, internal consistency, inter-rater reliability, sensitivity, specificity, and discriminant and convergent validity (Addington et al., 1992). Non-remitted MDD was defined by current antidepressant treatment (unchanged for more than 8 weeks) and current Calgary score  $\geq 6$  (Guillaume Fond et al., 2018).

Chronic peripheral low-grade inflammation was defined by a High sensitivity CRP (hs-CRP)  $\geq 3$  mg/L (Fond et al., 2016) and was measured with an assay using nephelometry (Dade Behring) blinded to schizophrenia status.

#### *Sociodemographic, clinical, treatments and biological variables*

The clinical scales, metabolic data and cognitive tests have been previously comprehensively described (Schürhoff et al., 2015) and are available in supplementary material. As the clinical evaluation and the biological analyses were separated in time and location, the clinical evaluation and the biological analyses were both blinded.

Solid phase-enzyme microplate immunoassay methods were used to measure IgG class of antibodies to *T. gondii* in blood sample. The results were quantified by calculating a ratio between the reactivity of the samples and a standard sample run on each microplate. Latent Toxoplasma infection was defined by *T. gondii* IgG ratio  $\geq 0.8$ , equivalent to  $\geq 10$  international units. All samples were analysed under code by the laboratory not having access to diagnostic or clinical information.

#### *Ethical concerns*

The study was carried out in accordance with ethical principles for medical research involving humans (WMA, Declaration of Helsinki). The assessment protocol was approved by the relevant ethical review board (CPP-Ile de France IX, January 18th, 2010). All data were collected anonymously. As this study include data coming from regular care assessments, a non-opposition form was signed by all participants.

#### *Statistical analysis*

Socio-demographics, clinical characteristics, addictive behaviour, treatments, biological variables and cognition are presented using measures of means and dispersion (standard deviation) for continuous data and frequency distribution for categorical variables. The data were examined for normal distribution with the Shapiro-Wilk test and for homogeneity of variance with the Levene test. Comparisons between respectively ID and NID regarding demographic, clinical and biological variables were performed using the chi-square test for categorical variables. Continuous variables were analysed with Student t-tests for normally

distributed data and in case of normality violation, additional Mann-Whitney tests were performed to confirm the result.

Variables with P values < 0.20 in univariate analysis were included in the multivariate analysis (PANSS disorganized factor, clozapine treatment, tricyclic and Norepinephrine antidepressants, triglyceride disturbance, glycaemic disturbance, increased abdominal perimeter and latent Toxoplasma Infection). Age and gender were forced. The final models included odds ratios and 95 % confidence intervals. This study was a confirmatory analysis. No correction for multiple testing has therefore been carried out, which is consistent with recommendations (Bender and Lange, 2001). Analyses were conducted using SPSS 17.0 software (SPSS Inc., Chicago, IL). All statistical tests were two-tailed, with  $\alpha$  level set at 0.05.

## Results

785 subjects recruited in the FACE-SZ cohort were included in the present study. 289 (36.8%) were diagnosed with MDD (remitted or unremitted), 57 with ID (19.7%) (flow chart figure 1).

Clinical, cognitive, addictive, biological and treatment characteristics of ID subjects are presented in table 1. ID patients were not found to differ from the others by their clinical or cognitive profile. In the multivariate model, ID has been associated with increased abdominal perimeter (aOR=4.48[1.73-11.60], p=0.002) and latent Toxoplasma infection (aOR=2.19[1.02-4.73], p=0.04) compared to non-ID after adjustment for age, gender, disorganization, clozapine and antidepressants administration and other metabolic disturbances.

Antidepressants were found to be associated with lower depressive symptoms level in both ID and non-ID subjects after adjustment for age, gender and hsCRP blood levels (respectively aOR=0.62[0.44-0.89], p=0.009 and aOR= 0.78[0.71-0.86], p<0.0001). CRP blood levels were not found to differ between antidepressant-treated and untreated subjects and between remitters and non-remitters (all p>0.05).

## Discussion

The present findings may be summarized as follows: ID was identified in almost one on five SZ patients with major depression. ID subjects were found to have

increased abdominal perimeter and higher frequency of latent *Toxoplasma* infection after adjustment for confounding variables. Antidepressants were effective in ID subjects however around 44% of them remained unremitted under conventional treatment.

We found no association between ID and lifestyle (sleep disorders, physical activity) but a strong association with body mass index and abdominal perimeter. It should be underlined that diet has not been explored to date in the FACE-SZ cohort due to a lack of validated diet questionnaire in French psychiatric populations. Diet may strongly influence both intra-abdominal fat and depression and should be explored in the future. Increased abdominal perimeter is a marker of intra-abdominal fat and has been associated with depressive symptoms in non-SZ populations (Everson-Rose et al., 2009; Klakk et al., 2018; Remigio-Baker et al., 2014) and with both white and gray matter brain abnormalities (Kharabian Masouleh et al., 2018, 2016; Zhang et al., 2018). There is now multiple evidence for a bidirectional relationship between depression and increased adiposity, with overweight/obesity being associated with an increased prevalence of depression, and in turn, depression augmenting the risk of weight gain and obesity (for review see (Capuron et al., 2017)). Hypothalamic-pituitary-adrenal (HPA) axis activation occurs in the state of stress; concurrently, the HPA axis is also dysregulated in obesity and metabolic syndrome, making it the most well-understood shared common pathophysiological pathway with depression (Lee et al., 2016). Numerous studies have investigated the effects of different classes of antidepressants on body weight. Previous clinical studies suggest that the tricyclics amitriptyline, nortriptyline and imipramine, and the serotonin norepinephrine reuptake inhibitor mirtazapine are associated with weight gain. Despite the fact that selective serotonin reuptake inhibitor (SSRI) use has been associated with weight loss during acute treatment, a number of studies have shown that SSRIs may be associated with long-term risk of weight gain; however, because of high variability and multiple confounds in clinical studies, the long-term effect of SSRI treatment and SSRI exposure on body weight remains unclear (for review see (Lee et al., 2016)). An animal paradigm has shown that the combination of stress and antidepressants followed by long-term high-fat diet results, long after discontinuation of antidepressant treatment, in markedly increased weight, in excess of what is caused by high-fat diet alone (Lee et al., 2016).

Altogether, these results suggest that reducing abdominal fat should be a priority in the ID treatment in SZ patients.

The present findings found no difference between inflammatory and non-inflammatory depression in regard of cognitive function. This is probably due to the fact that no association of impaired cognition and depression has been found in the FACE-SZ cohort, while inflammation has been associated with cognitive impairment (Bulzacka et al., 2016). Future studies should explore the specific mechanisms of cognitive impairment in schizophrenia (that are probably multiple), that seems to be associated in part with chronic-low grade peripheral inflammation but not with major depression.

ID has been associated with latent *Toxoplasma* infection for the first time in the present study. *Toxoplasma gondii* is an apicomplexan protozoan intracellular parasite with a widespread distribution in both developed and developing countries. *Toxoplasma* has been extensively associated with schizophrenia onset risk in the general population (for meta-analysis see (Sutterland et al., 2015)) and has been identified as a major source of inflammation in SZ subjects (G. Fond et al., 2018). While our meta-analysis published in 2015 did not confirm an association between *Toxoplasma* and major depression (Sutterland et al., 2015), new conflicting results on the associations between *Toxoplasma* and depression have been published (Alvarado-Esquivel et al., 2016; Gale et al., 2016; Suvisaari et al., 2017). A new meta-analysis is warranted to explore the links between *Toxoplasma*, depression and inflammation. Much of the attention relating to the role of *Toxoplasma* infection in neuropsychiatric disorders has focused on the brain, where *Toxoplasma* tissue cysts can persist for extended periods of time. However, recent discoveries relating to the role of the gastrointestinal tract in cognition and behavior suggest that *Toxoplasma* may also increase susceptibility to human brain diseases through immune activation, particularly involving the gastrointestinal mucosa (for review see (Severance et al., 2016)).

To make a long story short, these two potential etiological tracks for ID onset in schizophrenia seem to converge on the gastrointestinal track. The so-called “psychomicrobiotic” currently appears as one of the most promising strategies to improve psychiatric treatments (for review see (G. Fond et al., 2015)).

The higher rates of second-line treatments (clozapine and tricyclic agents) may explain the absence of difference of depressive symptoms severity / effectiveness

of antidepressants between ID and non-ID. Moreover, this absence highlights the need to develop reliable biomarkers to orientate treatments in psychiatry (Guillaume Fond et al., 2015). While alcohol use disorder has been associated with ID in non-SZ population (Archer et al., 2018), this association has not been replicated in the present sample. This may be due to the low rate of alcohol use disorder in our population and should be explored in SZ populations with higher frequency of alcohol use disorders. We found no association between childhood trauma and ID, which is consistent with a recent study carried out in non-SZ population (Mackinnon et al., 2018). A meta-analysis should determine if childhood adversity is associated with increased risk of inflammation in adulthood.

**Strengths.** The FACE-SZ cohort is unique by its sample size and longitudinal studies are needed to determine depression trajectories in SZ patients.

**Limits.** In addition to the above-mentioned limits, race/ethnicity has not been reported due to ethical issues. Leptin and inflammatory cytokines (IL-6, IL-1, TNF alpha) should be added in future studies to improve the ID signature (Milaneschi et al., 2017). The Toxoplasma strain and Toxo IgG serointensity have not been measured, as they are not validated in routine clinical practice. There is still a debate on the pro-inflammatory or anti-inflammatory properties of tricyclic agents that should be further explored (Fond et al., 2016; Hannestad et al., 2011; Köhler et al., 2018). Genetic disposition to inflammation may also influence antidepressant response (Zwicker et al., 2018).

**Perspectives.** Diet, microbiota disturbances, gut permeability, hypovitaminosis D have not been explored in the present study and should be targeted in future studies exploring ID in schizophrenia. Anti-inflammatory, in particular, the administration of anticytokines, including the monoclonal antibody against TNF- $\alpha$ , infliximab, may represent a useful strategy for the treatment of ID in schizophrenia (Capuron et al., 2017).

## Conclusion

ID may not differ from other forms of depression but these differences may have been erased by ID patients being administered more aggressive antipsychotic and antidepressant medications. The present results suggest that ID may differ not by clinical symptoms but by its etiologies: ID has been associated with both intra-abdominal fat and latent Toxoplasma infection, two tracks that encourage researchers

to explore the gut-brain axis to develop effective treatments in a precision medicine approach.

### **Acknowledgments and funding source**

The FACE-SZ group: Andrianarisoa M<sup>d,1</sup>, Aouizerate B<sup>a,1</sup>, MD PhD, Berna F<sup>b,1</sup>, MD PhD, Blanc O<sup>c,1</sup>, Msc, Brunel L<sup>d,1</sup>, Msc, Bulzacka E<sup>d,1</sup>, Msc, Capdevielle D<sup>e,1</sup>, MD PhD, Coulon N, Chereau-Boudet I<sup>c,1</sup>, MD, Chesnoy-Servanin G<sup>f,1</sup>, Msc, Danion JM<sup>b,1</sup>, MD, D'Amato T<sup>f,1</sup>, MD PhD, Deloge A<sup>g,1</sup>, MD PhD, Delorme C<sup>h,1</sup>, Msc, Denizot H<sup>c,1</sup>, MD, Dorey JM<sup>f,1</sup>, MD, Dubertret C<sup>i,1</sup>, MD PhD, Dubreucq J<sup>h,1</sup>, MD, Faget C<sup>j,1</sup>, MD, Fluttaz C<sup>h,1</sup>, Msc, Fond G<sup>j,1</sup>, MD, Fonteneau S<sup>k,1</sup>, Msc, Gabayet F<sup>h,1</sup>, Msc, Giraud-Baro E<sup>h,1</sup>, MD, Hardy-Bayle MC<sup>k,1</sup>, MD PhD, Lacelle D<sup>c,1</sup>, Msc, Lançon C<sup>j,1</sup>, MD PhD, Laouamri H<sup>l</sup>, Msc, Leboyer M<sup>d,1</sup>, MD PhD, Le Gloahec T<sup>d,1</sup>, Msc, Le Strat Y<sup>i,1</sup>, MD PhD, Llorca<sup>c,1</sup> PM, MD PhD, Mallet J<sup>i,1</sup>, Metairie E<sup>j,1</sup>, Msc, Misdrahi D<sup>g,1</sup>, MD, Offerlin-Meyer I<sup>b,1</sup>, PhD, Passerieux C<sup>k,1</sup>, MD PhD, Peri P<sup>j,1</sup>, Msc, Pires S<sup>c,1</sup>, Msc, Portalier C<sup>i,1</sup>, Msc, Rey R<sup>f,1</sup>, MD, Roman C<sup>h,1</sup>, Msc, Sebilleau M<sup>k,1</sup>, Msc, Schandrin A<sup>e,1</sup>, MD, Schürhoff F<sup>d,1</sup>, MD PhD, Tessier A<sup>g,1</sup>, Msc, Tronche AM<sup>c,1</sup>, MD, Urbach M<sup>k,1</sup>, MD, Vaillant F<sup>j,1</sup>, Msc, Vehier A<sup>f,1</sup>, Msc, Vidailhet P<sup>b,1</sup>, MD PhD, Vilà E<sup>g,1</sup>, Msc, Yazbek H<sup>e,1</sup>, PhD, Zinetti-Bertschy A<sup>b,1</sup>, Msc.

This work was funded by AP-HP (Assistance Publique des Hôpitaux de Paris), Fondation FondaMental (RTRS Santé Mentale), by the Investissements d'Avenir program managed by the ANR under reference ANR-11-IDEX-0004-02 and ANR-10-COHO-10-01, and by INSERM (Institut National de la Santé et de la Recherche Médicale).

We express all our thanks to the nurses, and to the patients who were included in the present study. We thank Hakim Laouamri, and his team (Stéphane Beaufort, Seif Ben Salem, Karmène Souyris, Victor Barteau and Mohamed Laaidi) for the development of the FACE-SZ computer interface, data management, quality control and regulatory aspects. We thank George Anderson for editorial assistance.

### **Conflicts of interest**

None declared.

## Contributors

GF and LB performed the statistical analysis. GF wrote the first complete manuscript. GF, LB and PML edited earlier versions of the manuscript for important intellectual content. All authors were involved in the patients' recruitment, the clinical evaluation, acquisition of the clinical data, modified the manuscript and approved the final version.

## REFERENCES

- Addington, D., Addington, J., Maticka-Tyndale, E., Joyce, J., 1992. Reliability and validity of a depression rating scale for schizophrenics. *Schizophr. Res.* 6, 201–208.
- Alvarado-Esquivel, C., Sanchez-Anguiano, L.F., Hernandez-Tinoco, J., Berumen-Segovia, L.O., Torres-Prieto, Y.E., Estrada-Martinez, S., Perez-Alamos, A.R., Ortiz-Jurado, M.N., Molotla-de-Leon, G., Beristain Garcia, I., Rabago-Sanchez, E., Liesenfeld, O., 2016. Toxoplasma gondii Infection and Mixed Anxiety and Depressive Disorder: A Case-Control Seroprevalence Study in Durango, Mexico. *J. Clin. Med. Res.* 8, 519–523. <https://doi.org/10.14740/jocmr2576w>
- Archer, M., Niemelä, O., Hämäläinen, M., Moilanen, E., Leinonen, E., Kampman, O., 2018. The effects of adiposity and alcohol use disorder on adipokines and biomarkers of inflammation in depressed patients. *Psychiatry Res.* 264, 31–38. <https://doi.org/10.1016/j.psychres.2018.03.073>
- Batty, G.D., Jung, K.J., Lee, S., Back, J.H., Jee, S.H., 2018. Systemic inflammation and suicide risk: cohort study of 419 527 Korean men and women. *J. Epidemiol. Community Health* 72, 572–574. <https://doi.org/10.1136/jech-2017-210086>
- Bender, R., Lange, S., 2001. Adjusting for multiple testing—when and how? *J. Clin. Epidemiol.* 54, 343–349. [https://doi.org/10.1016/S0895-4356\(00\)00314-0](https://doi.org/10.1016/S0895-4356(00)00314-0)
- Berk, M., Williams, L.J., Jacka, F.N., O'Neil, A., Pasco, J.A., Moylan, S., Allen, N.B., Stuart, A.L., Hayley, A.C., Byrne, M.L., Maes, M., 2013. So depression is an inflammatory disease, but where does the inflammation come from? *BMC Med.* 11, 200. <https://doi.org/10.1186/1741-7015-11-200>
- Brundin, L., Erhardt, S., Bryleva, E.Y., Achtyes, E.D., Postolache, T.T., 2015. The role of inflammation in suicidal behaviour. *Acta Psychiatr. Scand.* 132, 192–203. <https://doi.org/10.1111/acps.12458>
- Bulzacka, E., Boyer, L., Schürhoff, F., Godin, O., Berna, F., Brunel, L., Andrianarisoa, M., Aouizerate, B., Capdevielle, D., Chéreau-Boudet, I., Chesnoy-Servanin, G., Danion, J.-M., Dubertret, C., Dubreucq, J., Faget, C., Gabayet, F., Le Gloahec, T., Llorca, P.-M., Mallet, J., Misdrahi, D., Rey, R., Richieri, R., Passerieux, C., Roux, P., Yazbek, H., Leboyer, M., Fond, G., FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group, 2016. Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset. *Schizophr. Bull.* 42, 1290–1302. <https://doi.org/10.1093/schbul/sbw029>
- Cáceda, R., Griffin, W.S.T., Delgado, P.L., 2018. A probe in the connection between inflammation, cognition and suicide. *J. Psychopharmacol. Oxf. Engl.* 32, 482–488. <https://doi.org/10.1177/0269881118764022>

Capuron, L., Lasselin, J., Castanon, N., 2017. Role of Adiposity-Driven Inflammation in Depressive Morbidity. *Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol.* 42, 115–128.  
<https://doi.org/10.1038/npp.2016.123>

Everson-Rose, S.A., Lewis, T.T., Karavolos, K., Dugan, S.A., Wesley, D., Powell, L.H., 2009. Depressive symptoms and increased visceral fat in middle-aged women. *Psychosom. Med.* 71, 410–416.  
<https://doi.org/10.1097/PSY.0b013e3181a20c9c>

Faugere, M., Micoulaud-Franchi, J.-A., Faget-Agius, C., Lançon, C., Cermolacce, M., Richieri, R., 2018. High C-reactive protein levels are associated with depressive symptoms in schizophrenia. *J. Affect. Disord.* 225, 671–675.  
<https://doi.org/10.1016/j.jad.2017.09.004>

Fond, G., Boukouaci, W., Chevalier, G., Regnault, A., Eberl, G., Hamdani, N., Dickerson, F., Macgregor, A., Boyer, L., Dargel, A., Oliveira, J., Tamouza, R., Leboyer, M., 2015. The “psychomicrobiotic”: Targeting microbiota in major psychiatric disorders: A systematic review. *Pathol. Biol. (Paris)* 63, 35–42.  
<https://doi.org/10.1016/j.patbio.2014.10.003>

Fond, Guillaume, Boyer, L., Berna, F., Godin, O., Bulzacka, E., Andrianarisoa, M., Brunel, L., Aouizerate, B., Capdevielle, D., Chereau, I., Coulon, N., D’Amato, T., Dubertret, C., Dubreucq, J., Faget, C., Leignier, S., Lançon, C., Mallet, J., Misdrahi, D., Passerieux, C., Rey, R., Schandrin, A., Urbach, M., Vidailhet, P., Leboyer, M., Schürhoff, F., Llorca, P.-M., FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group, 2018. Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort. *Br. J. Psychiatry J. Ment. Sci.* 1–7. <https://doi.org/10.1192/bjpp.2018.87>

Fond, G., Boyer, L., Schürhoff, F., Berna, F., Godin, O., Bulzacka, E., Andrianarisoa, M., Brunel, L., Aouizerate, B., Capdevielle, D., Chereau, I., Coulon, N., D’Amato, T., Dubertret, C., Dubreucq, J., Faget, C., Lançon, C., Leignier, S., Mallet, J., Misdrahi, D., Passerieux, C., Rey, R., Schandrin, A., Urbach, M., Vidailhet, P., Llorca, P.M., Leboyer, M., FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group, Andrianarisoa, M., Aouizerate, B., Bazin, N., Berna, F., Blanc, O., Brunel, L., Bulzacka, E., Capdevielle, D., Chereau-Boudet, I., Chesnoy-Servanin, G., Coulon, N., Danion, J.M., D’Amato, T., Deloge, A., Denizot, H., Dorey, J.M., Dubertret, C., Dubreucq, J., Faget, C., Fluttaz, C., Fond, G., Fonteneau, S., Gabayet, F., Giraud-Baro, E., Jarroir, M., Leignier, S., Lacelle, D., Lançon, C., Laouamri, H., Leboyer, M., Le Gloahec, T., Le Strat, Y., Llorca, P.M., Mallet, J., Metairie, E., Misdrahi, D., Offerlin-Meyer, I., Passerieux, C., Peri, P., Pires, S., Portalier, C., Ramet, L., Rey, R., Roman, C., Schandrin, A., Schürhoff, F., Tessier, A., Tronche, A.M., Urbach, M., Vaillant, F., Vehier, A., Vidailhet, P., Vilà, E., Yazbek, H., Zinetti-Bertschy, A., 2018. Latent toxoplasma infection in real-world schizophrenia: Results from the national FACE-SZ cohort. *Schizophr. Res.*  
<https://doi.org/10.1016/j.schres.2018.05.007>

Fond, Guillaume, d’Albis, M.-A., Jamain, S., Tamouza, R., Arango, C., Fleischhacker, W.W., Glenthøj, B., Leweke, M., Lewis, S., McGuire, P., Meyer-Lindenberg, A., Sommer, I.E., Winter-van Rossum, I., Kapur, S., Kahn, R.S., Rujescu, D., Leboyer, M., 2015. The promise of biological markers for treatment response in first-episode psychosis: a systematic review. *Schizophr. Bull.* 41, 559–573.  
<https://doi.org/10.1093/schbul/sbv002>

Fond, G., Godin, O., Brunel, L., Aouizerate, B., Berna, F., Bulzacka, E., Capdevielle,

D., Chereau, I., Dorey, J.M., Dubertret, C., Dubreucq, J., Faget, C., Gabayet, F., Le Strat, Y., Micoulaud-Franchi, J.A., Misdrahi, D., Rey, R., Richieri, R., Passerieux, C., Schandrin, A., Schürhoff, F., Tronche, A.M., Urbach, M., Vidalhet, P., Llorca, P.M., Leboyer, M., FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group, 2016. Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set. *J. Affect. Disord.* 191, 209–215. <https://doi.org/10.1016/j.jad.2015.11.017>

Fond, G., Resseguier, N., Schürhoff, F., Godin, O., Andrianarisoa, M., Brunel, L., Bulzacka, E., Aouizerate, B., Berna, F., Capdevielle, D., Chereau, I., D'Amato, T., Dubertret, C., Dubreucq, J., Faget, C., Gabayet, F., Lançon, C., Llorca, P.M., Mallet, J., Misdrahi, D., Passerieux, C., Rey, R., Schandrin, A., Urbach, M., Vidailhet, P., Boyer, L., Leboyer, M., FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group, 2017. Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort. *Eur. Arch. Psychiatry Clin. Neurosci.* <https://doi.org/10.1007/s00406-017-0847-1>

Gale, S.D., Berrett, A.N., Brown, B., Erickson, L.D., Hedges, D.W., 2016. No association between current depression and latent toxoplasmosis in adults. *Folia Parasitol. (Praha)* 63. <https://doi.org/10.14411/fp.2016.032>

Hannestad, J., DellaGioia, N., Bloch, M., 2011. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. *Neuropsychopharmacology* 36, 2452–2459.

Kharabian Masouleh, S., Arélin, K., Horstmann, A., Lampe, L., Kipping, J.A., Luck, T., Riedel-Heller, S.G., Schroeter, M.L., Stumvoll, M., Villringer, A., Witte, A.V., 2016. Higher body mass index in older adults is associated with lower gray matter volume: implications for memory performance. *Neurobiol. Aging* 40, 1–10. <https://doi.org/10.1016/j.neurobiolaging.2015.12.020>

Kharabian Masouleh, S., Beyer, F., Lampe, L., Loeffler, M., Luck, T., Riedel-Heller, S.G., Schroeter, M.L., Stumvoll, M., Villringer, A., Witte, A.V., 2018. Gray matter structural networks are associated with cardiovascular risk factors in healthy older adults. *J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab.* 38, 360–372. <https://doi.org/10.1177/0271678X17729111>

Klakk, H., Kristensen, P.L., Andersen, L.B., Froberg, K., Møller, N.C., Grøntved, A., 2018. Symptoms of depression in young adulthood is associated with unfavorable clinical- and behavioral cardiovascular disease risk factors. *Prev. Med. Rep.* 11, 209–215. <https://doi.org/10.1016/j.pmedr.2018.05.017>

Köhler, C.A., Freitas, T.H., Stubbs, B., Maes, M., Solmi, M., Veronese, N., de Andrade, N.Q., Morris, G., Fernandes, B.S., Brunoni, A.R., Herrmann, N., Raison, C.L., Miller, B.J., Lanctôt, K.L., Carvalho, A.F., 2018. Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis. *Mol. Neurobiol.* 55, 4195–4206. <https://doi.org/10.1007/s12035-017-0632-1>

Lançon, C., Auquier, P., Reine, G., Bernard, D., Toumi, M., 2000. Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS). *J. Affect. Disord.* 58, 107–115.

Lee, S.H., Paz-Filho, G., Mastronardi, C., Licinio, J., Wong, M.-L., 2016. Is increased antidepressant exposure a contributory factor to the obesity pandemic? *Transl. Psychiatry* 6, e759. <https://doi.org/10.1038/tp.2016.25>

Mackinnon, N., Zammit, S., Lewis, G., Jones, P.B., Khandaker, G.M., 2018. Association between childhood infection, serum inflammatory markers and intelligence: findings from a population-based prospective birth cohort study. *Epidemiol. Infect.* 146, 256–264. <https://doi.org/10.1017/S0950268817002710>

Milaneschi, Y., Lamers, F., Bot, M., Drent, M.L., Penninx, B.W.J.H., 2017. Leptin Dysregulation Is Specifically Associated With Major Depression With Atypical Features: Evidence for a Mechanism Connecting Obesity and Depression. *Biol. Psychiatry* 81, 807–814. <https://doi.org/10.1016/j.biopsych.2015.10.023>

Remigio-Baker, R.A., Allison, M.A., Schreiner, P.J., Szklo, M., Crum, R.M., Leoutsakos, J.-M., Franco, M., Carnethon, M.R., Nettleton, J.A., Mujahid, M.S., Diez Roux, A.V., Jansky, N., Golden, S.H., 2014. Difference by sex but not by race/ethnicity in the visceral adipose tissue-depressive symptoms association: the Multi-Ethnic Study of Atherosclerosis. *Psychoneuroendocrinology* 47, 78–87. <https://doi.org/10.1016/j.psyneuen.2014.05.004>

Schürhoff, F., Fond, G., Berna, F., Bulzacka, E., Vilain, J., Capdevielle, D., Misdrahi, D., Leboyer, M., Llorca, P.-M., FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) collaborators, 2015. A National network of schizophrenia expert centres: An innovative tool to bridge the research-practice gap. *Eur. Psychiatry J. Assoc. Eur. Psychiatr.* <https://doi.org/10.1016/j.eurpsy.2015.05.004>

Severance, E.G., Xiao, J., Jones-Brando, L., Sabunciyan, S., Li, Y., Pletnikov, M., Prandovszky, E., Yolken, R., 2016. *Toxoplasma gondii*-A Gastrointestinal Pathogen Associated with Human Brain Diseases. *Int. Rev. Neurobiol.* 131, 143–163. <https://doi.org/10.1016/bs.irn.2016.08.008>

Sutterland, A.L., Fond, G., Kuin, A., Koeter, M.W.J., Lutter, R., van Gool, T., Yolken, R., Szoke, A., Leboyer, M., de Haan, L., 2015. Beyond the association. *Toxoplasma gondii* in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. *Acta Psychiatr. Scand.* <https://doi.org/10.1111/acps.12423>

Suvisaari, J., Torniainen-Holm, M., Lindgren, M., Härkänen, T., Yolken, R.H., 2017. *Toxoplasma gondii* infection and common mental disorders in the Finnish general population. *J. Affect. Disord.* 223, 20–25. <https://doi.org/10.1016/j.jad.2017.07.020>

Valkanova, V., Ebmeier, K.P., Allan, C.L., 2013. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. *J. Affect. Disord.* 150, 736–744. <https://doi.org/10.1016/j.jad.2013.06.004>

Zhang, R., Beyer, F., Lampe, L., Luck, T., Riedel-Heller, S.G., Loeffler, M., Schroeter, M.L., Stumvoll, M., Villringer, A., Witte, A.V., 2018. White matter microstructural variability mediates the relation between obesity and cognition in healthy adults. *NeuroImage* 172, 239–249. <https://doi.org/10.1016/j.neuroimage.2018.01.028>

Zwicker, A., Fabbri, C., Rietschel, M., Hauser, J., Mors, O., Maier, W., Zobel, A., Farmer, A., Aitchison, K.J., McGuffin, P., Lewis, C.M., Uher, R., 2018. Genetic disposition to inflammation and response to antidepressants in major depressive disorder. *J. Psychiatr. Res.* 105, 17–22. <https://doi.org/10.1016/j.jpsychires.2018.08.011>